Brepocitinib (PF06700841; PF-06700841) is a potent, selective, and conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor of TYK2 and JAK1 kinases with anti-inflammatory effects.

Ritlecitinib (PF-06651600) is a novel, potent, selective and irreversible/covalent JAK3 inhibitor with the potential to treat autoimmune diseases such as arthritis and Alopecia areata.

Upadacitinib (also known as ABT-494; ABT494; Rinvoq) is a novel, potent and selective Janus kinase (JAK) 1 inhibitor with immunomodulatory activity.

FM-381 HCl is a Chemical Probe For JAK3 and JAK3 specific reversible covalent inhibitor.

NSC 42834 (also known as JAK2 Inhibitor V) is a novel, potent and specific inhibitor of JAK2 which inhibits JAK2-V617F and JAK2-WT autophosphorylation in a dose-dependent manner with IC50 values between 10 and 30 µM.

Cucurbitacin E, a naturally occurring triterpene analog isolated from the climbing stem of Cucumic melo L with a potential therapeutic agent for metabolic diseases, significantly suppresses the activity of the cyclin B1/CDC2 complex.

JANEX-1 (aslo known as WHI-P131) is a novel, potent and selective inhibitor of the Janus kinase 3 (JAK3) that selectively inhibits JAK3 with an IC50 of 78 µM and does not inhibit JAK1 and JAK2.

AT9283 is a novel, potent multikinase inhibitor with potential antineoplastic activity and has the potential for the treatment of multiple myeloma.

Deucravacitinib (formerly BMS986165; BMS-986165; Tyk2-IN-4; Sotyktu) is a first-in-class, highly potent, orally bioavailable, selective and allosteric inhibitor of TYK2 (tyrosine kinase 2, a JAK family member/enzyme) in Phase 3 clinical studies across multiple immune-mediated diseases such as psoriatic arthritis, lupus and inflammatory bowel disease.

FM-381 (FM381) is a potent, specific, covalent reversible inhibitor of JAK3 with anti-inflammatory activity.